All In Biotech

Drug Trial Radar · NCT07228624

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Peri-Hematopoietic Cell Transplantation Ruxolitinib in Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Feb 4, 2026

Primary completion

Sep 1, 2030

Study completion Sep 1, 2030

Sponsor

Lead sponsor
Fred Hutchinson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Incyte Corporation
First posted
Nov 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests the effect of adding ruxolitinib to standard graft versus host disease (GVHD) prevention in treating older patients with myelofibrosis (MF) or myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes before, during, and after a donor (allogeneic) hematopoietic cell transplant (HCT). Allogeneic HCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical donor. Giving chemotherapy, such as cytoxan and busulfan or fludarabine and melphalan, before a donor transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. However, sometimes the transplanted cells from a donor can attack the body's normal cells (called GVHD). Giving standard prevention (prophylaxis) therapies, such as tacrolimus and methotrexate, after the transplant may stop this from happening. Methotrexate, a type of antifolate, is in a class of medications called antimetabolites. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Tacrolimus is used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Ruxolitinib, a type of Janus-associated kinase (JAK) inhibitor, blocks a protein called JAK, which may help keep abnormal blood cells or cancer cells from growing. It may also lower the body's immune response and prevent the development of GVHD. Giving ruxolitinib before, during and after allogeneic HCT in addition to standard GVHD prophylaxis may be safe, tolerable and effective in preventing GVHD and improving outcomes in older patients with MF or MDS/MPN overlap syndrome.

Conditions

  • Myelodysplastic/Myeloproliferative Neoplasm
  • Primary Myelofibrosis
  • Secondary Myelofibrosis

Interventions

  • RuxolitinibDrug

    Given PO or via nasogastric tube

  • Allogeneic Hematopoietic Stem Cell TransplantationProcedure

    Given infusion

  • BusulfanDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT

  • CyclophosphamideDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo echocardiography

  • FludarabineDrug

    Given IV

  • JAK InhibitorDrug

    Given JAK inhibitor

  • MelphalanDrug

    Given IV

  • MethotrexateDrug

    Given IV

  • TacrolimusDrug

    Given IV or PO

  • Biospecimen CollectionProcedure

    Undergo urine and blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow biopsy and aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy and aspiration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of grade II-IV graft versus host disease (GVHD) requiring systemic immune suppressionTime frame: Up to day-100

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.